Aquestive Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Warren, NJ
AQST chart
What traders are saying about $AQST
Latest postsAquestive Therapeutics, Inc. news
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
Yahoo Finance ·
- Aquestive Therapeutics, Inc. Estimates – NASDAQ:AQST
TradingView ·
- H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Moomoo ·
- AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST)
ChartMill ·
- Form 4 Aquestive Therapeutics Inc: John Cochran (Director) For: 21 October
Investing.com Nigeria ·
- A 62,229-share transfer leaves Aquestive (AQST) director holding 161,715 shares directly.
Stock Titan ·
- Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Yahoo Finance ·
- Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Yahoo Finance ·
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Yahoo Finance ·
- Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Yahoo Finance ·
- Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
Yahoo Finance ·
- Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Yahoo Finance ·
Aquestive Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M |
| Diluted EPS | $-0.78 | $-0.51 | $-0.13 | $-1.12 |
| Total assets (year end) | $160.4M | $101.4M | $57.4M | $57.1M |
| Cash and equivalents (year end) | $121.2M | $71.5M | $23.9M | $27.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Aquestive Therapeutics, Inc.
- Ticker
- AQST (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Warren, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1398733
- Former names
- MonoSol Rx, Inc.
Frequently asked questions
What exchange is Aquestive Therapeutics, Inc. listed on?
Aquestive Therapeutics, Inc. trades on the Nasdaq under the ticker symbol AQST.
What industry is Aquestive Therapeutics, Inc. in?
Aquestive Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc.'s business address on file with the SEC is in Warren, NJ.
When does Aquestive Therapeutics, Inc.'s fiscal year end?
Aquestive Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Aquestive Therapeutics, Inc. report?
Aquestive Therapeutics, Inc. reported $44.5M in revenue for calendar year 2025, according to its SEC filings.